Real-time Multiple Sclerosis Tracking App Debuts


The Novartis mobile app aims to track the physical and cognitive condition of patients on a daily basis.

elevateMS, mobile app, Novartis

A mobile phone app will help researchers conduct a data-based study of the everyday machinations and effects of multiple sclerosis (MS).

The Novartis study, Evaluation of Evidence from Smart Phone Sensors and Patient-Reported Outcomes in Participants with Multiple Sclerosis (elevateMS), will feature a downloadable mobile app that will collect patient questionnaire responses, passive and active sensor-based movement data, and performance tasks completed by patients. Advocates, neurologists and patients were gauged on the app’s interface, utility and intent prior to its release.

It was built on the Apple ResearchKit platform, and is available for download through the Apple App Store.

Novartis told MD Magazine in an email that the intent of a mobile research study is to develop new patient-centric clinical research endpoints — differing from conventional testing of MS symptom burdens.

“These assessments can feel unrelatable when viewed from most patients’ perspectives,” the company said. “We need to get better at measuring the things that really matter to patients, like how well they can function physically and cognitively during their everyday lives, outside of the clinic.”

The app and study collection is available to both MS patients and non-patients, and participants have the right to leave the study anytime they would like. User privacy is ensured, as every participant’s data will be delivered under an anonymous, random code.

Though a major focus of the study is to analyze how treatments and medication are affecting actual patients in their daily lives, there’s still importance for civilian input.

“We are hoping that several thousand MS patients participate,” the company said. “We also need people without MS to participate — all of the data helps us. Based on other experiences with the Apple ResearchKit platform, we expect about one-third of the participants to be MS patients.”

MS real-time tracking via a mobile app has been planned by Novartis for over a year. But a desire to research the day-to-day effects of a neurological condition has been long-held.

“As physicians, we always want to know how our patients with MS are doing on the treatments we prescribe,” Stanley Cohan, MD, PhD, medical director of Providence Multiple Sclerosis Center, Portland, Oregon, said in a statement. “With the elevateMS app, study participants can frequently document their symptoms in a personal health story.”

The elevateMS app is compatible with iPhone, iPad, and iPod touch devices, and require iOS 10.0 or later. It is available to download for free here.

Related Coverage

Why Older Male MS Patients Are More Prone to Depression

The Human Gut: The Next Frontier for MS Therapies

Study Highlights Promise, Questions in Quest for Stem Cell-based MS Treatments

Related Videos
How to Adequately Screen for and Treat Cognitive Decline in Primary Care
James R. Kilgore, DMSc, PhD, PA-C: Cognitive Decline Diagnostics
Stephanie Nahas, MD, MSEd | Credit: Jefferson Health
John Harsh, PhD: Exploring Once-Nightly Sodium Oxybate Therapy for Narcolepsy
John Harsh, PhD
© 2024 MJH Life Sciences

All rights reserved.